이중특이성항체 시장 : 작용기서, 치료 영역, 최종사용자별 - 세계 예측(2025-2030년)

The Bispecific Antibodies Market was valued at USD 5.71 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 32.64%, to USD 41.29 billion by 2030.

Bispecific antibodies are engineered proteins that can simultaneously bind to two different types of antigens, making them a vital innovation in the field of immunotherapy and cancer treatment. Their scope is significant as they provide a means to target multiple pathways in diseases, potentially enhancing therapeutic efficacy and reducing resistance compared to monoclonal antibodies. The necessity for bispecific antibodies stems from their ability to improve treatment specificities and outcomes, especially in oncology and autoimmune diseases. The application extends beyond cancer, with potential in infectious diseases and inflammatory conditions. The end-use scope involves hospitals, research institutes, and pharmaceutical industries, leveraging their unique capabilities for better patient outcomes. Key growth factors include an increasing incidence of target diseases, advancements in genetic engineering, and expanding R&D investments aimed at enhancing therapeutic applications. Demand is bolstered by ongoing clinical trials and regulatory approvals, placing emphasis on personalized medicine. However, market growth is challenged by the complexity in manufacturing, high cost of development, potential side effects, and stringent regulatory requirements. Latest opportunities reveal an emerging market need for biosimilars and cost-effective production methods. Companies are encouraged to explore collaborations for clinical trials, harness CRISPR technology to optimize antibody properties, and focus on next-generation bispecific antibody platforms. Areas prime for innovation include enhancing targeting precision, minimizing off-target effects, and developing multi-specific antibodies beyond the bispecific framework. Increased use of artificial intelligence and big data analytics can revolutionize development processes, leading to better patient stratification and treatment customization. While the market shows promise with current advancements, navigating cost and complexity issues remains essential for further growth. The competitive environment is shaped by rapid technological progress, necessitating continuous innovation and strategic partnerships to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bispecific Antibodies Market

The Bispecific Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of infectious and chronic illnesses globally
  • Advancements in genetic engineering and protein engineering technologies
  • Growing regulatory support for the development and approval of novel bispecific antibodies
• Market Restraints
  • Complexities in the manufacturing of bispecific antibodies
• Market Opportunities
  • Emerging trend toward personalized therapeutic approaches
  • Expanding usage of bispecific antibodies in the treatment of rare diseases
• Market Challenges
  • Issues associated with the safety and efficacy of bispecific antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Bispecific Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bispecific Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

Market Share Analysis: Understanding the Competitive Landscape in the Bispecific Antibodies Market

A detailed market share analysis in the Bispecific Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bispecific Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bispecific Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bispecific Antibodies Market

A strategic analysis of the Bispecific Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Alligator Bioscience AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Mechanism of Action, market is studied across Dual Antigen Targeting, Dual-Blocking Antibodies, and T-cell Engagers.
• Based on Therapeutic Area, market is studied across Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Oncology.
• Based on End-user, market is studied across Hospitals & Specialist Clinics and Research Institutions & Academic Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Michigan, Montana, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of infectious and chronic illnesses globally
    • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
    • 5.1.1.3. Growing regulatory support for the development and approval of novel bispecific antibodies
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in the manufacturing of bispecific antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging trend toward personalized therapeutic approaches
    • 5.1.3.2. Expanding usage of bispecific antibodies in the treatment of rare diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with the safety and efficacy of bispecific antibodies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
  • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
  • 5.2.3. End-user: Provision of comprehensive therapeutic care in hospitals and specialist clinics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry

6. Bispecific Antibodies Market, by Mechanism of Action

• 6.1. Introduction
• 6.2. Dual Antigen Targeting
• 6.3. Dual-Blocking Antibodies
• 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Infectious Diseases
• 7.4. Neurological Disorders
• 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals & Specialist Clinics
• 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Merck & Co Inc expands oncology portfolio with acquisition of novel bispecific antibody for B-cell malignancies
  • 12.3.2. Novartis collaborates with Dren Bio, for innovative bispecific antibodies to revolutionize cancer treatments
  • 12.3.3. Johnson & Johnson's Acquisition of Numab Therapeutics Boosting Bispecific Antibody Pipeline
  • 12.3.4. Regeneron highlights promising anti-tumor activity of novel bispecific antibody REGN7075
  • 12.3.5. Zenas Biopharma raises USD 200 Million in Series C Funding
  • 12.3.6. Invenra and Astellas Pharma form strategic partnership to enhance bispecific antibody R&D using the B-Body platform
  • 12.3.7. Biotheus and Hansoh Pharma expand partnership to develop innovative bispecific antibody-drug conjugates for cancer treatment
  • 12.3.8. FDA approves Johnson & Johnson's TECVAYLI for biweekly dosing in multiple myeloma
  • 12.3.9. AstraZeneca advances cancer treatment with innovative bispecific antibodies targeting multiple tumor antigens
  • 12.3.10. Janssen's TALVEY talquetamab-tgvs receives FDA accelerated approval
  • 12.3.11. FDA greenlights AbbVie and Genmab's EPKINLY for relapsed or refractory DLBCL
  • 12.3.12. Pfizer's elranatamab receives priority review by US FDA and EMA with positive trial results
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. AbbVie Inc.
  • 12.4.2. AstraZeneca PLC
  • 12.4.3. F. Hoffmann-La Roche Ltd.
  • 12.4.4. Amgen Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adimab, LLC
• 3. Affimed GmbH
• 4. Alligator Bioscience AB
• 5. Amgen Inc.
• 6. Astellas Pharma Inc.
• 7. AstraZeneca PLC
• 8. Bristol-Myers Squibb
• 9. Eli Lilly and Company
• 10. Emergent BioSolutions Inc.
• 11. F. Hoffmann-La Roche Ltd.
• 12. Genmab A/S
• 13. Gilead Sciences, Inc.
• 14. Innovent Biologics, Inc.
• 15. Johnson & Johnson Services, Inc.
• 16. Merck KGaA
• 17. Mereo Biopharma Group PLC
• 18. Merus N.V.
• 19. Novartis AG
• 20. Pfizer Inc.
• 21. Pieris Pharmaceuticals, Inc.
• 22. Regeneron Pharmaceuticals Inc.
• 23. Sanofi S.A.
• 24. TG Therapeutics, Inc.
• 25. Xencor, Inc.